Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neurology

Can Muscle Strength Recover After a Delayed IMNM Diagnosis?

At a Glance

After a delayed diagnosis of immune-mediated necrotizing myopathy (IMNM), many people can still regain meaningful strength and daily function. Treatment must first control the immune attack, while rehabilitation strengthens remaining muscle; permanent fat or scar tissue may limit recovery.

In this answer

3 sections

01

Understanding Muscle Damage and the “Window of Opportunity”

02

Halting Progression with Specialist-Directed Treatment

03

Regaining Function Through Physical Therapy

Yes, meaningful recovery of muscle strength and daily function is still possible even if your diagnosis and treatment for Immune-mediated necrotizing myopathy (IMNM) were delayed [1][2][3]. While a long delay can lead to permanent structural changes in some muscles, prompt, specialist-directed medical treatment can stop the disease from progressing [4][5]. Once the immune attack is controlled, targeted physical therapy can help your remaining healthy muscle fibers become stronger and more efficient, allowing many patients to regain important aspects of their independence [6][7].

Important Safety Note: If you experience new or worsening difficulty swallowing, choking during meals, shortness of breath, or a sudden inability to stand or walk, contact your care team or seek emergency medical help immediately [8][9].

Understanding Muscle Damage and the “Window of Opportunity”

In IMNM, the immune system mistakenly attacks and destroys muscle cells. Doctors often discuss a “window of opportunity” early in the disease course when treatment can prevent permanent damage [10][11][12]. However, missing this early window does not mean recovery is impossible. A delayed diagnosis is common in rare diseases, and it is not your fault.

When IMNM is left untreated, two distinct processes can occur:

  • Muscle Atrophy: A loss of muscle bulk. This can happen from the disease itself or simply from not moving as much due to weakness. Atrophy from disuse can often improve with targeted rehabilitation [13].
  • Fatty Replacement and Fibrosis: Over time, destroyed muscle tissue can be permanently replaced by fat and scar tissue [14][13][15]. Unlike healthy muscle, fat and scar tissue cannot contract or generate strength. This structural damage cannot be reversed [4].

Because of fatty replacement, a long delay in treatment may mean that your muscles will not return to 100% of their pre-illness strength. However, the amount of recovery varies widely depending on your specific antibody subtype (such as anti-HMGCR or anti-SRP), disease severity, and how your body responds to medication [16][17]. Furthermore, lingering weakness is not always a sign of permanent damage; it can also result from general deconditioning or side effects from medications like corticosteroids.

Halting Progression with Specialist-Directed Treatment

Even if some permanent fatty replacement has occurred, starting prompt medical treatment is critical [4]. Medical treatments—which are highly individualized and may include corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIG), or targeted biologic drugs—aim to shut down the immune attack [4][5].

Stopping ongoing muscle damage protects your remaining healthy muscle fibers and creates an environment where rehabilitation can be effective. Studies and case reports indicate that even patients who have experienced profound, longstanding weakness can achieve meaningful disease control and functional improvement with intensive medical therapy [18][6][1].

Regaining Function Through Physical Therapy

Rehabilitation should be coordinated closely with your neuromuscular care team. Doctors often monitor blood tests for the muscle enzyme creatine kinase (CK) to help gauge disease activity, but a normal CK is not the only sign that you are ready for physical therapy, nor does it guarantee strength [19][20].

Physical therapy often begins gently—even while you are still receiving medical treatment—with range-of-motion and safe-transfer exercises [6]. Because you cannot regrow the muscle fibers that were permanently lost, rehabilitation works by training your remaining healthy muscle fibers [6]. A physical therapist experienced with neuromuscular diseases will guide you through an individualized program that includes:

  • Targeted strengthening: Progressively loading the healthy muscle so it can adapt and compensate for damaged tissue [6].
  • Endurance training: Improving your muscles’ ability to sustain activity over time [21].
  • Functional adaptation: Learning safe, new ways to perform practical daily tasks, such as getting out of a chair, walking, and preventing falls [7].

Recovery from a delayed IMNM diagnosis is rarely immediate. It often takes months of consistent effort, and progress may plateau at times. However, a structured approach that combines medical disease control with targeted rehabilitation can lead to significant improvements in your ability to navigate daily life safely [6][7].

Common questions in this guide

Can I regain strength after a delayed IMNM diagnosis?
Yes, meaningful improvements in muscle strength and daily function can still happen after delayed treatment. Permanent muscle damage may prevent a complete return to your pre-illness strength, but medical treatment and rehabilitation can still improve independence.
What can limit recovery when IMNM treatment is delayed?
Ongoing immune damage can destroy muscle fibers and replace them with fat and scar tissue, which cannot contract. Weakness can also result from muscle loss due to inactivity, general deconditioning, or medication effects, some of which may improve.
What treatments help stop further muscle damage from IMNM?
Depending on your condition and treatment response, a specialist may use corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIG), or targeted biologic medicines. These treatments aim to stop the immune attack and protect remaining healthy muscle.
When can physical therapy start after an IMNM diagnosis?
Physical therapy may begin gently during medical treatment with range-of-motion and safe-transfer exercises. A normal creatine kinase (CK) level is not the only measure of readiness, so your neuromuscular team should set the pace and monitor your symptoms.
How long does it take to improve strength after delayed IMNM treatment?
Recovery often takes months and varies according to the amount of muscle damage, disease control, and response to rehabilitation. Progress may plateau at times, so your care team can help set realistic functional goals and adjust the plan.
When does IMNM weakness require urgent medical help?
Seek urgent medical help for new or worsening difficulty swallowing, choking during meals, shortness of breath, or a sudden inability to stand or walk. These symptoms should not wait for a routine appointment.

Related questions

Is Dark, Tea-Colored Urine an Emergency in IMNM? What to Do Does IMNM Cause Severe Muscle Pain? Evaluation and Care Does Statin-Induced IMNM Go Away After Stopping Statins? Do IMNM Antibody Levels Correlate With Disease Activity? What Are the Early Warning Signs of an IMNM Relapse?
Show more
Can Anti-SRP IMNM Cause Heart and Lung Complications? How Do I Find an IMNM Specialist or Referral Center? How to Read Your IMNM Muscle Biopsy Pathology Report How Does IMNM Affect Life Expectancy and Prognosis? Why Was I Initially Diagnosed With Muscular Dystrophy? Is Exercise Safe With IMNM? Weightlifting Guidance Is Immune-Mediated Necrotizing Myopathy Hereditary? How Is IVIG Used for Immune-Mediated Necrotizing Myopathy? What Are New and Experimental Treatments for IMNM? What Cancer Screening Is Needed for Seronegative IMNM? What Is Triple Therapy for IMNM? Medicines Explained How Does IMNM Cause Trouble Swallowing (Dysphagia)? What Are Typical CK Levels During an Active IMNM Flare? Why Is an MRI Used to Diagnose IMNM? What It Shows

Get notified when new evidence is published on Immune-mediated necrotizing myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Dysphagia as the Initial Manifestation of Anti-HMGCR Antibody-Positive Immune-Mediated Necrotizing Myopathy Complicated by Pulmonary Embolism.

    Kalluri R, Ciofoaia E, Adetimehin O, et al.

    Case reports in rheumatology 2026; (2026()):2235175 doi:10.1155/crrh/2235175.

    PMID: 42984811
  2. 2

    Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report.

    Patel S, Abu-Abaa M, Mousavi F

    Cureus 2022; (14(8)):e27824 doi:10.7759/cureus.27824.

    PMID: 36106264
  3. 3

    Statin-Associated Immune-Mediated Necrotizing Myopathy: An Underrecognised Cause of Progressive Muscle Weakness in Primary Care.

    Ong JT, Jamil TR, Loo SY

    Cureus 2026; (18(3)):e105830 doi:10.7759/cureus.105830.

    PMID: 42037837
  4. 4

    Therapeutic management of immune-mediated necrotizing myositis.

    Weeding E, Tiniakou E

    Current treatment options in rheumatology 2021; (7(2)):150-160 doi:10.1007/s40674-021-00174-1.

    PMID: 34422547
  5. 5

    Challenges in the diagnosis and management of immune-mediated necrotising myopathy (IMNM) in a patient on long-term statins.

    Khan F, Brady S, Kuttikat A

    Rheumatology international 2023; (43(2)):383-390 doi:10.1007/s00296-022-05230-0.

    PMID: 36260115
  6. 6

    Refractory Severe Anti-SRP Myopathy that Improved with Long-term Rehabilitation Therapy: A Case Report.

    Nakao Y, Ibe Y, Tazawa M, et al.

    Progress in rehabilitation medicine 2025; (10()):20250003 doi:10.2490/prm.20250003.

    PMID: 39845980
  7. 7

    INPATIENT REHABILITATION AND FUNCTIONAL OUTCOME OF A CASE OF ANTI-SRP IMMUNE-MEDIATED NECROTIZING MYOPATHY.

    Chen N, Yamin Thein K, San Tay S

    Journal of rehabilitation medicine. Clinical communications 2024; (7()):40653 doi:10.2340/jrm-cc.v7.40653.

    PMID: 39444782
  8. 8

    Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.

    Watanabe Y, Uruha A, Suzuki S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2016; (87(10)):1038-44 doi:10.1136/jnnp-2016-313166.

    PMID: 27147697
  9. 9

    Increasing recognition of statin-associated anti-HMGCR antibody-positive autoimmune myopathy: a single-center retrospective study.

    Mali M, Pirilä L, Jokela M, et al.

    Clinical rheumatology 2026; (45(6)):3517-3524 doi:10.1007/s10067-026-08136-5.

    PMID: 42053859
  10. 10

    Clinical Characteristics and Management of Statin-Associated Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy.

    Yoon J, Kim SW, Kim SH, et al.

    Journal of clinical medicine 2025; (14(18)) doi:10.3390/jcm14186610.

    PMID: 41010829
  11. 11

    Management of immune-mediated necrotizing myopathy.

    Suh J, Amato AA

    Muscle & nerve 2024; (70(2)):166-172 doi:10.1002/mus.28114.

    PMID: 38801022
  12. 12

    Outcome predictors of immune-mediated necrotizing myopathy-a retrospective, multicentre study.

    Wang JX, Wilkinson M, Oldmeadow C, et al.

    Rheumatology (Oxford, England) 2022; (61(9)):3824-3829 doi:10.1093/rheumatology/keac014.

    PMID: 35022671
  13. 13

    Statin-naïve anti-HMGCR antibody-mediated necrotizing myopathy in China.

    Jiao Y, Cai S, Lin J, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2018; (57()):13-19 doi:10.1016/j.jocn.2018.08.010.

    PMID: 30205933
  14. 14

    Pediatric Immune-Mediated Necrotizing Myopathy: A Single-Center Retrospective Cohort Study.

    Wang Y, Yang M, Zhao Y, et al.

    Pediatric neurology 2025; (167()):33-41 doi:10.1016/j.pediatrneurol.2025.03.002.

    PMID: 40203548
  15. 15

    Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies.

    Fionda L, Lauletta A, Leonardi L, et al.

    Journal of neurology 2023; (270(2)):960-974 doi:10.1007/s00415-022-11447-7.

    PMID: 36329184
  16. 16

    Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.

    Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al.

    Annals of the rheumatic diseases 2017; (76(4)):681-687 doi:10.1136/annrheumdis-2016-210198.

    PMID: 27651398
  17. 17

    Immune-Mediated Necrotizing Myopathy.

    Pinal-Fernandez I, Casal-Dominguez M, Mammen AL

    Current rheumatology reports 2018; (20(4)):21 doi:10.1007/s11926-018-0732-6.

    PMID: 29582188
  18. 18

    Clinical and histological features of immune-mediated necrotising myopathy: A multi-centre South Australian cohort study.

    Day J, Otto S, Cash K, Limaye V

    Neuromuscular disorders : NMD 2020; (30(3)):186-199 doi:10.1016/j.nmd.2020.02.003.

    PMID: 32229165
  19. 19

    Cohort study of 23 patients with seropositive immune-mediated necrotizing myopathy.

    Batton R, Roullée L, Carrette M, et al.

    La Revue de medecine interne 2026; (47(8)):415-423 doi:10.1016/j.revmed.2026.07.006.

    PMID: 42562677
  20. 20

    Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.

    Ramanathan S, Langguth D, Hardy TA, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2015; (2(3)):e96 doi:10.1212/NXI.0000000000000096.

    PMID: 25866831
  21. 21

    Physical therapy in adult inflammatory myopathy patients: a systematic review.

    Van Thillo A, Vulsteke JB, Van Assche D, et al.

    Clinical rheumatology 2019; (38(8)):2039-2051 doi:10.1007/s10067-019-04571-9.

    PMID: 31115788

This page is for informational purposes only and does not constitute medical advice. Your neuromuscular care team should assess disease activity and tailor treatment, rehabilitation, and safe activity to your situation.